The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases.

For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival.

Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology

Biomedical Advanced Research and Development Authority (BARDA)

CARB-X

Hambro Perks Ltd.

SV Investment Corp

Shinhan Capital

Shinhan Private Equity

FC Capital

Partners Investment

QUAD Investment Management

Health for Life Capital fund

Skyviews Life Science

SymBiosis LLC

Verition Fund Management

Rock Springs Capital

Shumway Capital

JSR Corp

Magnetar Capital

PureTech Health

Revelation Partners

Korea Investment Holdings

Korea Investment Partners

AMR Action Fund

Atlantic Neptune

Fiscus Ventures

Peak 6

Pfizer Breakthrough Growth Initiative

Vedanta Biosciences, Inc.

Colorcon Ventures, the corporate venture fund of Colorcon® Inc., has invested in Vedanta Biosciences, Inc., a clinical stage life sciences company that designs and manufactures proprietary, orally delivered bacterial therapies.

Ali Rajabi-Siahboomi, Vice President and Chief Innovation Officer at Colorcon, said, “Vedanta Biosciences is aligned with Colorcon Ventures’ interest in emerging classes of drugs for oral administration. The company’s unique approach within microbial therapeutics has the potential to offer safer and more efficacious treatments for a number of indications. Vedanta has also revolutionized the manufacturing of defined bacterial consortia at scale, which adds significant value to the sector. We look forward to supporting Vedanta Biosciences as they realize the full potential of their platform technology.”

Press Release ➡️https://hubs.ly/Q02lRXmx0

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Apple Mobile Web Clips Icon

HSTS

Google Font API

DNSSEC

Amazon

Chief Executive Officer

Bernat Olle

Chief Operating Officer

Daniel Couto

Chief Financial Officer

Mark Mullikin

Chief Legal Officer and Corporate Secretary

Simona Levi

Vice President Program Management and Operations Planning

Debra Winslow

Business Management

Jack Kyte

VP, Clinical Operations

Lorraine Hughes

Finance and Administration

Maggie McGuigan

Director, CMC Operations & Strategic Planning

Alicia Szretter

Manufacturing Manager

Ben Shapiro

John LaMattina

Chris Viehbacher

Curt LaBelle

Neil Tiwari

Troy Ignelzi

Martin Heidecker

Alexander Rudensky

Scientific Co-Founder

Dan Littman

CEO, Co-founder & Board of Directors

Ruslan Medzhitov

Co-Founder & Chair

Silvia Caballero

Director, Infectious Diseases

Jeffrey Silber

Chief Legal Officer

Cambridge Companies With More Than $10M in Revenue

New England Companies With Less Than $500M in Revenue (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Companies With More Than 50 Employees (Top 10K)

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally defined bacterial consortia in powder form to help physicians have access to live bacteria drugs to treat autoimmune and inflammatory diseases easily.

Grant - Vedanta Biosciences

Colorcon Ventures

Venture Round - Vedanta Biosciences

AXA Investment Managers

Series E - Vedanta Biosciences

Series D - Vedanta Biosciences

Secondary Market - Vedanta Biosciences

Debt Financing - Vedanta Biosciences

Series C - Vedanta Biosciences

Cambridge

Massachusetts

United States

North America

Vedanta Biosciences

Peanut Allergy Treatment Market Set to Surge at 11.6% CAGR, to Reach USD 1278.3 Million by 2032 | VMR

Microbiome Therapeutics Market to Hit $2.78 Billion by 2032, Fueled by Immune Disease Solutions

Microbiome Therapeutics Whitespace Analysis Reveals Market Opportunities | Second Genome, Inc., Vedanta Biosciences

Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of ...

Vedanta Biosciences doses first subject in Phase III C difficile prevention trial

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of ...

Vedanta awarded new funding from CARB-X to advance VE-707

Vedanta Biosciences, Inc. on LinkedIn: Vedanta Biosciences Awarded $3.9 Million from CARB-X to Ready VE707 for…

An orally administered, defined bacterial consortium developed for preventing Clostridioides difficile infection recurrence. It consists of 8 clonal human commensal bacteria strains.

A rationally-designed bacterial consortium candidate for the potential treatment of inflammatory bowel disease (IBD), consisting of clonal human commensal bacteria strains.

A preclinical program aimed at preventing infection and colonization recurrence of multi-drug resistant organisms, including CRE, ESBL, and VRE, through an orally administered bacterial consortium.

Vedanta has received research grants from CARB-X to support the development of VE303 for C. difficile infection treatment and VE707 for preventing MDRO infections.

A Phase 2 trial evaluating the efficacy of VE303 in preventing recurrence of Clostridioides difficile infection, which met its primary efficacy endpoint.

Luxembourg

Europe

Israel

Asia

HTML5

DigiCert

Vimeo

Google Analytics

Amazon EC2

Google Fonts

Office 365

Microsoft Outlook

Apache Server

Wistia

Alveolus develops therapeutics for lung diseases such as live biotherapeutics for various pulmonary conditions.

Alveolus

LISCure Biosciences is a competitor of Vedanta Biosciences in the biotechnology sector.

LISCure Biosciences

x-chemrx.com is a potential or emerging competitor with high similarity score to vedantabio.com.

news impact assignment basic	general	Mar 8, 2024 1:41 AM	a346781e
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 1:41 AM	34baa45b
company summary	general
signals	general	Mar 8, 2024 1:41 AM	21a0409c
crunchbase trigger	general	Nov 25, 2024 9:09 AM	78aa4f9f
crunchbase profile	general	Nov 25, 2024 12:04 PM	d25e7cf5
li profile	general	Mar 8, 2024 1:41 AM	a6442a99
translate crunchbase fundingrounds	general	Nov 25, 2024 1:51 PM	bcc9f63a
peers	general	Mar 8, 2024 1:41 AM	9a6e6fb0
news basic	general	Mar 8, 2024 1:41 AM	2b63c483
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:VEDANTABIO

Vedanta Biosciences